Data compiled by Redley Lamar · ChainSifter Intelligence
6Suppliers
1Customers
3Debt Items
9Related Chains
Source-Backed Evidence Depth
INmune Bio Inc. (INMB) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
11Total relationships
4Distinct source URLs
10High confidence
0.863Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
INmune Bio Inc. Suppliers
Ticker
Name
Confidence
Evidence
A-G-P-ALLIANCE-GLOBAL-PARTNERS
A-G-P-ALLIANCE-GLOBAL-PARTNERS
92%
The Company entered into a Sales Agreement with A.G.P./Alliance Global Partners, as sales agent, pursuant to which the Company may offer and sell, from time to time, through A.G.P., up to $65,000,000…
AMPLIFYBIO
AMPLIFYBIO
90%
At September 30, 2025 and December 31, 2024, the Company recorded a payable to AmplifyBio of $26,000 and $0, respectively, for medical research performed on behalf of the Company.
ANTHONY-NOLAN
ANTHONY-NOLAN
90%
Under the terms of the Amended and Restated Agreement, AN will be entitled to a royalty of 2% on net sales of each Product, as defined in the Amended and Restated Agreement
IMMUNE-VENTURES-LLC
IMMUNE-VENTURES-LLC
90%
In consideration for the INKmune License, we are obligated to pay Immune Ventures certain milestone and royalty payments.
VENDOR
VENDOR
80%
During April 2025, the Company’s wholly-owned subsidiary, INmune Bio International. Ltd., entered into a 2-year collaboration agreement with a vendor whereby it makes fixed payments to the vendor in …
Reciprocal relationship from XNCR graph: Reciprocal relationship from INMB graph: Reciprocal relationship from XNCR graph: Reciprocal relationship from INMB graph: Reciprocal relationship from XNCR g…
INmune Bio Inc. Customers
Ticker
Name
Confidence
Evidence
ANTHONY-NOLAN
ANTHONY-NOLAN
85%
In addition, AN will be entitled to fees equal to £400 plus VAT in respect of the Cell and Gene Therapies Services, as defined in the Amended and Restated Agreement, related to each umbilical cord tissue
INmune Bio Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
INMB-DEBT-10291
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2017-12-31.
INMB-DEBT-10290
Warrants outstanding: 1557592
90%
xbrl warrant detail from xbrl 2025-12-31.
INMB-DEBT
Debt stack $12.2M
90%
Market cache reports total debt of $12.2M.
INmune Bio Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for INmune Bio Inc..
INmune Bio Inc. Ownership
Holder
Name
Confidence
Evidence
INMB-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 82 tracked holders.
